Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.
30 mai 2023 16h15 HE
|
Landos Biopharma, Inc.
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
Landos Biopharma Announces 1-for-10 Reverse Stock Split
25 mai 2023 16h05 HE
|
Landos Biopharma, Inc.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
12 mai 2023 08h50 HE
|
Landos Biopharma, Inc.
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May ...
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
12 mai 2023 08h00 HE
|
Landos Biopharma, Inc.
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May ...
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
23 mars 2023 08h00 HE
|
Landos Biopharma, Inc.
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into...
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
28 févr. 2023 17h00 HE
|
Landos Biopharma, Inc.
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis...
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
11 janv. 2023 07h00 HE
|
Landos Biopharma, Inc.
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
05 janv. 2023 07h05 HE
|
Landos Biopharma, Inc.
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the...
Landos Biopharma Announces $16.7 Million Private Placement Financing
05 janv. 2023 07h00 HE
|
Landos Biopharma, Inc.
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for...
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
10 nov. 2022 08h00 HE
|
Landos Biopharma, Inc.
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...